Clinical Trial Search

Primary: Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline — 58.8; 67.6; 8.8 letters

Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…

Primary: Percentage Change in Retinal Thickness in the Study Eye at 6 Months Compared to Baseline — -7.89 percentage change in retinal thickness

Primary: Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 6 Months Compared to the Average of the Pre-treatment…

Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns

Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 — 17.5; 17.4; 18.3 Letters — p=<0.0001

Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…

Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters

Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…

Primary: Change in Central Subfield Thickening From Baseline Through 34 Weeks — -10; -47; -27; -16 microns — p=0.46

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Number of Participants Experiencing at Least One Adverse Events (AEs) — 13; 7 Participants

Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters

Primary: Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts. — 0.18; 0.36; 0.18 logMAR

Primary: Mean Change From Baseline in Best Correct Visual Acuity (BCVA) — 9.55 Letters